# Single Ascending Dose Study of the Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of HSD-016

> **NCT00740649** · PHASE1 · COMPLETED · sponsor: **Wyeth is now a wholly owned subsidiary of Pfizer** · enrollment: 74 (estimated)

## Conditions studied

- Healthy Subjects

## Interventions

- **DRUG:** HSD-016
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT00740649
- **Lead sponsor:** Wyeth is now a wholly owned subsidiary of Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-10
- **Primary completion:** 2009-03
- **Final completion:** 2009-03
- **Target enrollment:** 74 (ESTIMATED)
- **Last updated:** 2009-03-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00740649

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00740649, "Single Ascending Dose Study of the Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of HSD-016". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00740649. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*